Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Venook on Geographic Variations in Treatments
July 4th 2013, 5:36am
ESMO Gastrointestinal Cancers Congress
Alan P. Venook, MD, from the University of California, San Francisco, describes factors that contribute to the geographic variations seen in therapies utilized to treat cancer in the United States and Europe.
Novel Hsp Inhibitor May Offer NSCLC Salvage Option
June 7th 2013, 7:04am
Salvage therapy combining the novel heat shock protein 90 inhibitor ganetespib with docetaxel significantly improved overall survival in some patients with non–small cell lung cancer.
Axillary Radiotherapy Equal to Surgery in Early Breast Cancer
June 6th 2013, 11:50am
Women with early sentinel lymph node-positive breast cancer achieve as much of a disease-free and survival benefit from axillary radiotherapy as they do from axillary lymph node dissection with significantly less risk of lymphedema.
Optimal Paclitaxel Schedule Identified for Early-Stage Breast Cancer
June 4th 2013, 1:44pm
Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.
Dr. Hudis Highlights Two Abstracts From ASCO 2013
June 4th 2013, 1:25pm
Clifford A. Hudis, MD, ASCO President-Elect, describes the focus on global medicine at the 2013 American Society of Clinical Oncology Annual Meeting.
Vinegar Proves to Be Effective, Widely Implementable Cervical Cancer Screening Tool
June 4th 2013, 8:52am
A simple visual screening test using vinegar has the potential to dramatically reduce the number of deaths from cervical cancer in the developing world, according to findings from a large study in India, where use of the screening tool yielded a 31% reduction in cervical cancer mortality.
Drug Shortages Adversely Affect Treatment Decisions
June 3rd 2013, 1:26pm
Shortages of cancer drugs caused many oncologists and hematologists to choose suboptimal treatment plans for their patients last year, and government efforts have done little to boost the availability of the hard-to-find medications.
More Evidence for 10-Years of Tamoxifen in ER+ Breast Cancer
June 3rd 2013, 12:29pm
A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.
Dr. Gilbert Describes Ongoing RTOG 0825 Trial Analyses
June 3rd 2013, 10:03am
Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.
Bevacizumab Improves Survival in Advanced Cervical Cancer
June 3rd 2013, 7:40am
Bevacizumab combined with either of two chemotherapy backbones improved overall survival by 3.7 months versus chemotherapy alone in patients with advanced cervical cancer.
Dr. Ribas on Anti-PD-1 Agent Lambrolizumab in Melanoma
June 3rd 2013, 7:26am
Antoni Ribas, MD, PhD, from UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.
Dr. Ramalingam Reviews the GALAXY-1 Trial Results
June 3rd 2013, 6:59am
Suresh S. Ramalingam, MD, from the Winship Cancer Institute, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.
Sorafenib Doubles PFS in Rare Thyroid Cancer
June 3rd 2013, 5:34am
Interim findings from a randomized, global, phase III study indicate that the multi-targeted drug sorafenib nearly doubled PFS for patients with differentiated thyroid cancer resistant to radioactive iodine therapy.
First-Line Bevacizumab Does Not Improve Survival in Glioblastoma
June 2nd 2013, 1:14pm
Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.
Richard Gray on a Longer Duration of Tamoxifen
June 2nd 2013, 12:28pm
Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.
Dr. Brose on Sorafenib in RAI-Resistant Thyroid Cancer
June 2nd 2013, 10:33am
Marcia Brose, MD, PhD, from the Abramson Cancer Center at the University of Pennsylvania, discusses the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.
GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma
June 2nd 2013, 7:50am
Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.
Dr. Heinemann Reviews the FIRE-3 Trial Results
June 2nd 2013, 7:38am
Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.
Partners of HPV-Positive Oropharyngeal Cancer Patients Not at Increased Risk of HPV Infection or Oral Cancer
June 2nd 2013, 7:31am
Patients with human papilloma virus–positive oropharyngeal cancer and their spouses may find some reassurance in a study that found that partners are no more likely to be infected by HPV than the general population.
Maintenance Therapy With Pazopanib Delays Relapse of Advanced Ovarian Cancer
June 2nd 2013, 7:03am
An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.